GenScript Singapore's Open Day reveals pioneering AI capabilities in recombinant protein production and drug discovery

GenScript, a global leader in life sciences and biotechnology, successfully hosted an Open Day event at its Singapore facility on the 16th of April, welcoming more than 50 representatives from Singapore. This event provided an exclusive look into GenScript's state-of-the-art gene and protein production facility, particularly highlighting the company's advancements in artificial intelligence (AI)-driven gene and recombinant protein production. Guests embarked on a guided tour through the facility, witnessing the precision and efficiency with which GenScript integrates AI technology to enhance production.

The highlight during the event was the introduction of GenScript's latest AI innovations, which have been designed to optimise recombinant protein production and streamline processes in unprecedented ways.

GenScript has introduced GenSmart Codon Optimization, a free online tool designed to enhance gene sequence design for significantly improved expression in both prokaryotic and mammalian systems, covering more than 50 host organisms now.

GenScript is also utilising AI to develop other tools to accelerate enzyme and antibody discovery. The enzyme engineering platform - Al-deZyme, is designed to accelerate enzyme evolution via stability and activity optimszation. The antibody AI platform will be able to support in-silicon developability assessment & optimisation of antibody.

"Today, we stand at the cusp of a new era in biotechnology," said Dr Janice Jin, President at GenScript Asia Pacific. "The convergence of AI with therapeutic antibody development and drug discovery is not just an advancement of our capabilities—it's a revolution in how we approach complex biological challenges. Our Open Day was a showcase of this synergy and a promise of the collaborative triumphs to come."